Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México.
Hospital Civil de Guadalajara "Juan I. Menchaca", Servicio de Reumatología, PNPC, CONACyT, Guadalajara, Jalisco, México.
Immunopharmacol Immunotoxicol. 2021 Jun;43(3):328-333. doi: 10.1080/08923973.2021.1910833. Epub 2021 Apr 20.
The presence of myositis-specific antibodies (MSA), was recently reported in healthy individuals, cancer patients without myopathy and paraneoplastic rheumatic syndromes. We sought to analyze the frequency of MSA, myositis-associated antibodies (MAA) and autoantibodies related to systemic autoimmune rheumatic diseases (SARD) in breast cancer patients.
One hundred fifty-two breast cancer patients were enrolled in a cross-sectional study. Clinical information was collected, and autoantibodies tested by immunoprecipitation of an S-methionine-labeled K562 cell extract, enzyme-linked immunosorbent assay (ELISA) and Western blot when indicated. All statistical tests were performed using the software statistical package for the social science (SPSS) ver. 19.0 (IBM Inc., NYSE, USA).
Autoantibodies associated with SARD: anti-52 kD ribonucleoprotein/tripartite motif-containing 21 (anti-Ro52/TRIM21) was found in 5.9% (9/152), anti-Sjögren syndrome-related antigen A/60 kD ribonucleoprotein antibody (anti-SSA/Ro60) in 3.9% (6/152) and anti-Su antigen/Argonaute 2 antibody (anti-Su/Ago2) in 2.6% (4/152). Meanwhile, anti-transcription intermediary factor-1γ (anti-TIF-1γ, p155/140) antibody was positive in 2 cases and anti-polymyositis/scleroderma antibody was detected in one case. As a whole, 14.47% (22/152) of breast cancer patients showed autoantibodies associated with SARD. These specific autoantibodies were not associated with the presence of rheumatic diseases except one rheumatoid arthritis patient positive for anti-Ro52/TRIM21.
Autoantibodies to TIF-1γ were found in two patients with breast cancer without dermatomyositis (DM). More common specificities were autoantibodies anti-SSA/Ro60, anti-Ro52/TRIM21 and anti-Su/Ago2. More studies are needed in order to establish the biological meaning of the presence of SARD-associated autoantibodies in breast cancer.
最近有报道称，肌炎特异性抗体（MSA）存在于健康个体、无肌病的癌症患者和副肿瘤性风湿病患者中。我们旨在分析乳腺癌患者中肌炎相关抗体（MAA）和与系统性自身免疫性风湿病（SARD）相关的自身抗体的频率。
我们纳入了 152 名乳腺癌患者进行横断面研究。收集临床信息，并通过免疫沉淀 S-蛋氨酸标记的 K562 细胞提取物、酶联免疫吸附试验（ELISA）和 Western blot 检测自身抗体，当需要时进行。所有统计检验均使用社会科学统计软件包（SPSS）第 19.0 版（IBM Inc.，NYSE，USA）进行。
与 SARD 相关的自身抗体：抗 52 kD 核糖核蛋白/三部分结构域包含蛋白 21（抗 Ro52/TRIM21）在 5.9%（9/152）的患者中发现，抗干燥综合征相关抗原 A/60 kD 核糖核蛋白抗体（抗 SSA/Ro60）在 3.9%（6/152）的患者中发现，抗 Su 抗原/Argonaute 2 抗体（抗 Su/Ago2）在 2.6%（4/152）的患者中发现。同时，有 2 例抗转录中介因子 1γ（抗 TIF-1γ，p155/140）抗体阳性，1 例抗多发性肌炎/硬皮病抗体阳性。总的来说，14.47%（22/152）的乳腺癌患者存在与 SARD 相关的自身抗体。这些特异性自身抗体与风湿病无关，除了 1 例抗 Ro52/TRIM21 阳性的类风湿关节炎患者。
我们在两名无皮肌炎的乳腺癌患者中发现了针对 TIF-1γ的自身抗体。更常见的特异性自身抗体是抗 SSA/Ro60、抗 Ro52/TRIM21 和抗 Su/Ago2。需要进一步研究以确定乳腺癌中 SARD 相关自身抗体存在的生物学意义。
